 |
|
EGFR/HER2 tyrosine kinase inhibitor BIBW 2992
An orally bioavailable dual receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. EGFR/HER2 tyrosine kinase inhibitor BIBW 2992 irreversibly binds to and inhibits human epidermal growth factor receptors 1 and 2 (EGFR-1; HER2), which may result in the inhibition of tumor growth and angiogenesis. EGFR/HER2 are RTKs that belong to the EGFR superfamily; both play major roles in tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Synonym: | | dual tyrosine kinase inhibitor BIBW 2992 | | | | Abbreviation: | | EGFR/HER2 TKI BIBW 2992 | | | | Code name: | | BIBW 2992 | | |
|
|
